A team at UNAM is working on a transplant therapy that tries to do something current medicine rarely can. It aims to calm the immune system without suppressing it across the whole body. The plan is to train a patient’s own cells to protect a transplanted kidney rather than attack it. That could reduce dependence on lifelong anti-rejection drugs. The promise is clear. So is the gap between lab success and a treatment people can actually receive in Mexico.
A targeted approach to a difficult problem
UNAM researchers are developing a cell therapy to prevent kidney transplant rejection. The work is based at the National Laboratory of Flow Cytometry inside the university’s Institute of Biomedical Research. The goal is not just to protect a transplanted organ. It is to teach the immune system to tolerate it more precisely. If the approach works in people, it could reduce patients’ dependence on lifelong immunosuppressive drugs. That would mark a change in how transplant care is managed. This is still research, not a treatment hospitals can offer today.
The need for better tools is easy to see in Mexico. UNAM specialists said last year that roughly 12 percent of the population lives with chronic kidney disease. The same university report, citing official transplant data, said 16,675 people were waiting for a kidney transplant in 2024. That year, 2,723 kidney transplants were performed. The gap between need and available organs is only part of the problem. Once a patient receives a kidney, doctors still have to keep that organ working for years. A therapy that helps prevent rejection with fewer long-term side effects would matter in any country. In Mexico, where the disease burden is high, it would matter even more.
How the therapy works
The science behind the project centers on regulatory T cells, or Tregs. These cells help stop immune responses from going too far. The UNAM team is working on ways to isolate immune cells, expand them in the lab, and return them to the patient after they have been prepared to suppress the specific response that attacks the donated kidney. That targeted design is the point. Instead of lowering the body’s defenses broadly, the therapy aims to quiet the part of the immune system that treats the new organ as a threat.
That distinction matters because current transplant medicine still depends on broad immune suppression. Those drugs save kidneys and remain essential. But they also carry costs. Anti-rejection medicines can raise the risk of infection and, over time, increase the risk of cancer and other complications. They can also contribute to diabetes, high blood pressure, and damage to other organs. In practical terms, patients keep the transplant by living in a long-term medical tradeoff. Treg therapy tries to make that tradeoff less severe.
Why the project matters now
This is not new work that appeared overnight. Public UNAM materials show the project has been in development for years. In 2017, the lab described efforts to generate transplant-specific regulatory T cells as an alternative to drug-heavy treatment. By 2025, UNAM was presenting the work in innovation and startup forums. That same year, the university reopened LabNalCit in larger facilities. Those facilities include a good manufacturing practice area, which is a key step for advanced cell therapies. In other words, the project is moving beyond a basic laboratory concept and toward the harder task of clinical translation.
That harder task is now the central issue. The March 16 update says the preclinical phase is complete, and the next step is human research. That step is expensive. It also requires strict production standards and regulatory approval. The team says it needs about $2 million to build that bridge and seek licensing from Cofepris. This is the stage where many promising biomedical projects stall. The science may be sound. But turning carefully grown cells into a real therapy means proving safety, consistency, and benefit under clinical rules.
What readers should take from it
The right way to read this story is with interest and restraint. Patients should not treat it as a near-term replacement for prescribed medicine. Early international studies of Treg-based transplant therapy have produced encouraging results, especially on safety and feasibility. But the field is still young. The strongest evidence so far points to a possible reduction in immune attack and drug burden, not a finished substitute for standard care. In one early human kidney study, recipients still needed reduced immunosuppression rather than full withdrawal.
That does not make the UNAM project less important. It makes it easier to judge fairly. The realistic short-term goal may be lower toxicity, fewer complications, and better long-term organ survival, not the immediate end of anti-rejection drugs. Even that would be significant. For readers in Mexico, this story is also about something larger than a single transplant method. It shows a public university working to translate a high-level biomedical idea into the health system. If the platform advances, similar immune-training strategies could later be explored for other transplants and some autoimmune diseases.
For now, the most honest conclusion is simple. UNAM has a promising platform, not a finished treatment. Yet in a country with a large kidney disease burden and long transplant waiting lists, even a modest reduction in rejection or drug-related harm would matter. The coming test is no longer whether the idea is scientifically interesting. It is whether the project can secure enough support to reach patients.
With information from Gaceta UNAM
